Total health expenditure is determined by two key factors: the price of healthcare services and drugs, and the volume of services utilized. This article delves into the prices and utilization of healthcare services in the United States in comparison to other high-income nations. While data availability is limited to specific services and pharmaceuticals, our analysis reveals that elevated prices, more significantly than higher utilization rates, are the primary driver behind the United States’ substantial healthcare spending relative to comparable countries.
Available international data indicates that the U.S. faces considerably higher prices for a wide array of healthcare services and prescription medications. Conversely, the utilization of several services, including consultations with physicians and hospital admissions, is actually lower in the U.S. compared to many similar countries. However, there are exceptions; the use of certain procedures like C-sections and knee replacements is more prevalent in the U.S. than in comparable nations.
Despite exhibiting fewer doctor’s office visits and shorter average durations of hospital stays, the United States’ overall healthcare expenditure per person is double that of comparable countries.
This analysis complements a previous study on how healthcare prices have evolved in the U.S. over time, demonstrating the historical trend of rising healthcare service costs in the nation.
Related Content:
Health Spending
How has U.S. spending on healthcare changed over time?
Access & Affordability
How Medicare negotiated drug prices compare to other countries
Comparing Healthcare Expenditure: Wealthy Countries Spend Significantly Less Per Person Than the U.S.
In 2016, healthcare spending in the U.S. constituted 18% of its GDP, surpassing Switzerland, the next highest country, which allocated 12% of its GDP to healthcare. The average healthcare expenditure per person in comparable countries stands at $5,198, approximately half of the U.S.’s expenditure of $10,348. This stark contrast underscores the substantial difference in healthcare spending, indicating a significant area for price comparison and analysis.
Physician Consultations: U.S. Residents Visit Doctors Less Frequently Than in Comparable Countries
With the exception of Sweden, the U.S. exhibits the lowest rate of physician consultations per capita among similarly affluent countries. In 2015, comparable countries averaged 7.6 total consultations per person across physician offices, hospital outpatient departments, and emergency rooms, while the U.S. averaged only 3.9 consultations per person. This data suggests that lower utilization of physician services is not the reason for higher costs, pointing towards price discrepancies.
It is also relevant to note that the U.S. has a lower density of physicians per capita compared to similar countries, with 2.6 physicians per 1,000 people in 2013 versus the comparable country average of 3.4. This factor might influence access but doesn’t fully explain the spending gap without considering price.
Consistent Trend: Fewer Physician Visits in the U.S. Compared to Other Wealthy Nations Over Time
The disparity in physician consultation rates is not a recent phenomenon. In 2000, the U.S. already had approximately 46% fewer physician consultations per capita compared to similarly wealthy countries, and this gap has remained relatively consistent. The 2015 figures, as mentioned earlier (7.6 consultations per person in comparable countries vs. 3.9 in the U.S.), reinforce this enduring trend. This historical perspective further emphasizes the need to Compare Prices And understand their role in the spending difference.
Hospital Stays: U.S. Patients Experience Shorter Hospitalizations
Shorter hospital stays can be more cost-effective, assuming quality of care is maintained. However, they can also lead to increased costs per day and service intensity. Patients in the U.S. experience significantly shorter average hospital stays (6 days) compared to patients in comparable countries (10 days). This lower utilization metric again points away from volume as the main cost driver, emphasizing the importance of price comparison.
Long-Term Trend: Consistently Shorter Hospital Stays in the U.S.
The trend of shorter hospital stays in the U.S. is not new and has been observed over time. Average lengths of stay have been declining due to advancements in medical practices, technological improvements, and changes in hospital reimbursement models and financial pressures. Both the U.S. and comparable countries have witnessed similar rates of reduction in hospital stay durations since 1994, indicating a global shift, yet the cost difference persists, suggesting price as a crucial factor.
Hospital Prices: Higher Nightly Costs in the U.S.
Hospital expenditure constitutes a substantial 32% of total health spending in the U.S. Data from the International Federation of Health Plans reveals that while hospital stays are shorter in the U.S., the average price per night in a hospital is significantly higher than in Australia and slightly higher than in Switzerland. This direct price comparison highlights a key area contributing to higher U.S. healthcare costs.
Heart Procedures: Angioplasty vs. Bypass Surgeries in the U.S.
The U.S. averages fewer angioplasty procedures and slightly more coronary bypass surgeries compared to comparable OECD countries. While both treat heart disease, bypass surgery is generally reserved for more severe cases. This difference in procedure mix, however, is overshadowed by the price disparities.
Price of Heart Procedures: Significantly Higher in the U.S.
While the U.S. performs a different mix of angioplasty and bypass surgeries, the average prices for both procedures are substantially higher than in comparable countries where data is available. The average price of an angioplasty in the U.S. is 183% higher than in Australia, the next highest among comparable countries with data. Coronary bypass surgery in the U.S. costs 129% more than in Switzerland, emphasizing the dramatic price difference. When we compare prices and consider these figures, the cost driver becomes clear.
Cesarean Sections: More Frequent in the U.S.
The U.S. has a higher rate of cesarean sections compared to most comparable wealthy countries. Although the rate has slightly decreased recently, after a significant increase between 1996 and 2009, it remains elevated. Cesarean deliveries, while sometimes necessary, are often more expensive and carry greater risks than natural deliveries, adding to overall costs, and their higher frequency in the U.S. contributes to spending differences.
Related Content:
Health Spending
How has U.S. spending on healthcare changed over time?
Health Spending
How much is health spending expected to grow?
Price of Cesarean Sections: Higher in the U.S. Compared to Others
In 2014, the average price of a normal delivery in the U.S. was $10,808, approximately 33% less than a cesarean section ($16,106). When we compare prices to similar countries with available data, both normal and cesarean deliveries are significantly more expensive in the U.S., further contributing to the overall higher healthcare costs.
MRI Availability and Use: U.S. Leads in Both
The U.S. has a greater availability of MRI units per million population and performs more MRI examinations per 1,000 people than the average of comparable countries. This high utilization of advanced imaging technology, coupled with price considerations, affects overall spending.
Price of MRIs: Substantially Higher in the U.S.
Despite higher utilization, the average price of an MRI in the U.S. in 2014 was $1,119. This is 42% more than in the UK, 122% more than in Switzerland, and a staggering 420% more than in Australia. The national 95th percentile average price of an MRI in the U.S. reaches $3,031. This price comparison clearly demonstrates a significant cost driver in U.S. healthcare.
Appendectomy Prices: Double the Cost in the U.S.
While the UK performs fewer appendectomies than the U.S., the price per surgery in the U.S. is $15,930, nearly double the UK price. In Australia and Switzerland, where appendectomy rates are even higher than in comparable countries, the prices are even lower, at $3,814 and $6,040 respectively. This price comparison reveals a large discrepancy and highlights the cost competitiveness in other nations.
Knee Replacements: More Frequent in the U.S.
Both the U.S. and comparable countries have seen an increase in knee replacements since 2000. However, the U.S. consistently performs more of these surgeries. In 2014, the U.S. averaged 227 knee replacements per 100,000 population, compared to 180 per 100,000 in comparable countries. Higher procedure volume, in addition to price, contributes to increased spending.
Price of Knee Replacements: Higher in the U.S.
The average price of a knee replacement in the U.S. in 2014 was $28,184, which is 40% more than in Switzerland, 53% more than in the UK, and 77% more than in Australia. This price comparison reinforces the trend of higher procedure costs in the U.S.
Hip Replacement Prices: Significantly Higher in the U.S.
The average price of a hip replacement in the U.S. is also considerably higher than in comparable countries where data is available. While specific percentages are not provided, the statement emphasizes a consistent pattern of elevated prices for orthopedic procedures in the U.S.
Colonoscopy Prices: UK Exceeds U.S. Prices
Interestingly, the average price of a colonoscopy in the UK is 135% higher than in the U.S. This is a notable exception to the general trend of higher U.S. prices and suggests that price dynamics can vary across different procedures.
Prescription Drug Prices: Humira Price Comparison
Humira, a drug for rheumatoid arthritis, is priced 96% higher in the United States than in the United Kingdom and 225% higher than in Switzerland. This significant price difference for a common medication underscores the issue of high drug costs in the U.S.
Xarelto Price Comparison: U.S. Prices More Than Double
Xarelto, used to prevent blood clots, is priced more than twice as high in the United States compared to the United Kingdom or Switzerland. This again highlights the substantial price markup for pharmaceuticals in the U.S. market.
Harvoni Price Comparison: U.S. Prices Significantly Higher
Harvoni, a high-cost specialty drug for Hepatitis C, is priced 42% higher in the United States than in the United Kingdom and 90% higher than in Switzerland. The high cost of specialty drugs further exacerbates the overall healthcare spending issue in the U.S.
Truvada Price Comparison: U.S. Prices Remain Elevated
Truvada, for HIV/AIDS treatment, is priced 44% higher in the United States than in Switzerland and 89% higher than in the United Kingdom. Even for essential medications, the U.S. faces significantly higher prices.
Tecfidera Price Comparison: Extreme Price Disparity
Tecfidera, for multiple sclerosis, is priced 174% higher in the United States than in Switzerland and an astonishing 668% higher than in the United Kingdom. This extreme price difference showcases the vast range in pharmaceutical pricing across countries.
Avastin Price Comparison: Cancer Drug Costs More in the U.S.
Avastin, used to treat certain cancers, is priced 124% higher in Switzerland and 125% higher than in the United Kingdom. Even for life-saving cancer treatments, the U.S. faces significantly higher price points.
About this site
The Peterson Center on Healthcare and KFF are partnering to monitor how well the U.S. healthcare system is performing in terms of quality and cost.
[
